Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

ASP1126, a Novel Sphingosine-1-Phosphate-Selective Agonist With a Favorable Safety Profile, Prolongs Allograft Survival in Rats and Nonhuman Primates in Combination With Tacrolimus With a Broad Safety Margin for Bradycardia.

Okimoto A, Yamamoto R, Hirose J, Shimatani K, Koshika T, Maeda M, Hattori K, Morokata T.

Transplant Proc. 2019 Jul - Aug;51(6):2081-2098. doi: 10.1016/j.transproceed.2019.05.012.

PMID:
31399186
2.

The PI3Kδ selective inhibitor AS2541019 suppresses donor-specific antibody production in rat cardiac and non-human primate renal allotransplant models.

Marui T, Fukahori H, Ito M, Kaneko Y, Maeda M, Tsujimoto S, Morokata T.

Int Immunopharmacol. 2019 Oct;75:105756. doi: 10.1016/j.intimp.2019.105756. Epub 2019 Jul 22.

PMID:
31344556
3.

AS2762900-00, a potent anti-human IL-23 receptor monoclonal antibody, prevents epidermal hyperplasia in a psoriatic human skin xenograft model.

Sasaki-Iwaoka H, Taguchi K, Okada Y, Imamura E, Kubo S, Furukawa S, Morokata T.

Eur J Pharmacol. 2019 Jan 15;843:190-198. doi: 10.1016/j.ejphar.2018.11.030. Epub 2018 Nov 22.

PMID:
30472202
4.

Effective suppression of donor specific antibody production by Cathepsin S inhibitors in a mouse transplantation model.

Kubo K, Kawato Y, Nakamura K, Nakajima Y, Nakagawa TY, Hanaoka K, Oshima S, Fukahori H, Inami M, Morokata T, Higashi Y.

Eur J Pharmacol. 2018 Nov 5;838:145-152. doi: 10.1016/j.ejphar.2018.09.007. Epub 2018 Sep 6.

PMID:
30196110
5.

Replacement of mycophenolate mofetil with a JAK inhibitor, AS2553627, in combination with low-dose tacrolimus, for renal allograft rejection in non-human primates.

Nakamura K, Oshima S, Maeda M, Morio H, Fukahori H, Nakanishi T, Tsujimoto S, Hirose J, Noto T, Hamakawa N, Inami M, Morokata T.

Int Immunopharmacol. 2018 Nov;64:201-207. doi: 10.1016/j.intimp.2018.08.029. Epub 2018 Sep 7.

PMID:
30195818
6.

Generation and characterization of a potent fully human monoclonal antibody against the interleukin-23 receptor.

Sasaki-Iwaoka H, Ohori M, Imasato A, Taguchi K, Minoura K, Saito T, Kushima K, Imamura E, Kubo S, Furukawa S, Morokata T.

Eur J Pharmacol. 2018 Jun 5;828:89-96. doi: 10.1016/j.ejphar.2018.03.036. Epub 2018 Mar 26.

PMID:
29588152
7.

Effects of AS2541019, a novel selective PI3Kδ inhibitor, on antibody production and hamster to rat xenotransplantation.

Marui T, Fukahori H, Kawashima T, Ito M, Akamatsu M, Kaneko Y, Takahashi F, Imada S, Morokata T.

Eur J Pharmacol. 2018 May 5;826:179-186. doi: 10.1016/j.ejphar.2018.02.046. Epub 2018 Mar 5.

PMID:
29518396
8.

Anti-IL-23 receptor monoclonal antibody prevents CD4+ T cell-mediated colitis in association with decreased systemic Th1 and Th17 responses.

Imamura E, Taguchi K, Sasaki-Iwaoka H, Kubo S, Furukawa S, Morokata T.

Eur J Pharmacol. 2018 Apr 5;824:163-169. doi: 10.1016/j.ejphar.2018.01.045. Epub 2018 Jan 31.

PMID:
29391156
9.

Prevention of chronic renal allograft rejection by AS2553627, a novel JAK inhibitor, in a rat transplantation model.

Nakamura K, Kawato Y, Kaneko Y, Hanaoka K, Kubo K, Nakanishi T, Maeda M, Fukahori H, Ito M, Noto T, Inami M, Hirose J, Morokata T.

Transpl Immunol. 2018 Feb;46:14-20. doi: 10.1016/j.trim.2017.10.001. Epub 2017 Oct 5.

PMID:
28988984
10.

Origin of Enriched Regulatory T Cells in Patients Receiving Combined Kidney-Bone Marrow Transplantation to Induce Transplantation Tolerance.

Sprangers B, DeWolf S, Savage TM, Morokata T, Obradovic A, LoCascio SA, Shonts B, Zuber J, Lau SP, Shah R, Morris H, Steshenko V, Zorn E, Preffer FI, Olek S, Dombkowski DM, Turka LA, Colvin R, Winchester R, Kawai T, Sykes M.

Am J Transplant. 2017 Aug;17(8):2020-2032. doi: 10.1111/ajt.14251. Epub 2017 Apr 10.

11.

ASP0028 in combination with suboptimal-dose of tacrolimus in Cynomolgus monkey renal transplantation model.

Dun H, Song L, Ma A, Hu Y, Zeng L, Bai J, Zhang G, Zhang L, Koide K, Okada Y, Hanaoka K, Yamamoto R, Hirose J, Morokata T, Daloze P, Chen H.

Transpl Immunol. 2017 Feb;40:57-65. doi: 10.1016/j.trim.2017.01.002. Epub 2017 Jan 7.

PMID:
28077266
12.

AS2553627, a novel JAK inhibitor, prevents chronic rejection in rat cardiac allografts.

Nakamura K, Inami M, Morio H, Okuma K, Ito M, Noto T, Shirakami S, Hirose J, Morokata T.

Eur J Pharmacol. 2017 Feb 5;796:69-75. doi: 10.1016/j.ejphar.2016.12.025. Epub 2016 Dec 16.

PMID:
27993641
13.

A chronic renal rejection model with a fully MHC-mismatched rat strain combination under immunosuppressive therapy.

Hanaoka K, Kawato Y, Kubo K, Nakanishi T, Maeda M, Nakamura K, Hirose J, Noto T, Fukahori H, Fujikawa A, Miyoshi S, Takakura S, Morokata T, Higashi Y.

Transpl Immunol. 2016 Sep;38:19-26. doi: 10.1016/j.trim.2016.08.002. Epub 2016 Aug 19.

PMID:
27545900
14.

Effect of novel PKCθ selective inhibitor AS2521780 on acute rejection in rat and non-human primate models of transplantation.

Fukahori H, Chida N, Maeda M, Tasaki M, Kawashima T, Noto T, Tsujimoto S, Nakamura K, Oshima S, Hirose J, Higashi Y, Morokata T.

Int Immunopharmacol. 2015 Aug;27(2):232-7. doi: 10.1016/j.intimp.2015.06.016. Epub 2015 Jun 26.

PMID:
26122135
15.

ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.

Yamamoto R, Okada Y, Hirose J, Koshika T, Kawato Y, Maeda M, Saito R, Hattori K, Harada H, Nagasaka Y, Morokata T.

PLoS One. 2014 Oct 27;9(10):e110819. doi: 10.1371/journal.pone.0110819. eCollection 2014.

16.

High-resolution modeling of antibody structures by a combination of bioinformatics, expert knowledge, and molecular simulations.

Shirai H, Ikeda K, Yamashita K, Tsuchiya Y, Sarmiento J, Liang S, Morokata T, Mizuguchi K, Higo J, Standley DM, Nakamura H.

Proteins. 2014 Aug;82(8):1624-35. doi: 10.1002/prot.24591. Epub 2014 May 13.

PMID:
24756852
17.

Pyrrolidinyl phenylurea derivatives as novel CCR3 antagonists.

Nitta A, Iura Y, Inoue H, Sato I, Morihira K, Kubota H, Morokata T, Takeuchi M, Ohta M, Tsukamoto S, Imaoka T, Takahashi T.

Bioorg Med Chem Lett. 2012 Nov 15;22(22):6876-81. doi: 10.1016/j.bmcl.2012.09.035. Epub 2012 Sep 20.

PMID:
23046963
18.

Discovery and structure-activity relationships of urea derivatives as potent and novel CCR3 antagonists.

Nitta A, Iura Y, Tomioka H, Sato I, Morihira K, Kubota H, Morokata T, Takeuchi M, Ohta M, Tsukamoto S, Imaoka T, Takahashi T.

Bioorg Med Chem Lett. 2012 Aug 1;22(15):4951-4. doi: 10.1016/j.bmcl.2012.06.042. Epub 2012 Jun 20.

PMID:
22749826
19.

In vitro and in vivo characterization of AS2643361, a novel and highly potent inosine 5'-monophosphate dehydrogenase inhibitor.

Nakanishi T, Kozuki Y, Eikyu Y, Kubo K, Kawato Y, Marui T, Seki N, Masunaga T, Tamura K, Morokata T.

Eur J Pharmacol. 2012 Jan 5;674(1):58-63. doi: 10.1016/j.ejphar.2011.10.032. Epub 2011 Oct 31.

PMID:
22075081
20.

Mechanisms of donor-specific tolerance in recipients of haploidentical combined bone marrow/kidney transplantation.

Andreola G, Chittenden M, Shaffer J, Cosimi AB, Kawai T, Cotter P, Locascio SA, Morokata T, Dey BR, Tolkoff-Rubin NT, Preffer F, Bonnefoix T, Kattleman K, Spitzer TR, Sachs DH, Sykes M.

Am J Transplant. 2011 Jun;11(6):1236-47. doi: 10.1111/j.1600-6143.2011.03566.x.

21.

Mixed chimerism, lymphocyte recovery, and evidence for early donor-specific unresponsiveness in patients receiving combined kidney and bone marrow transplantation to induce tolerance.

LoCascio SA, Morokata T, Chittenden M, Preffer FI, Dombkowski DM, Andreola G, Crisalli K, Kawai T, Saidman SL, Spitzer TR, Tolkoff-Rubin N, Cosimi AB, Sachs DH, Sykes M.

Transplantation. 2010 Dec 27;90(12):1607-15. doi: 10.1097/TP.0b013e3181ffbaff.

22.

Effect of the inosine 5'-monophosphate dehydrogenase inhibitor BMS-566419 on renal fibrosis in unilateral ureteral obstruction in rats.

Nakanishi T, Morokata T, Noto T, Kubo K, Umeno H, Kinugasa F, Eikyu Y, Kozuki Y, Seki N.

Int Immunopharmacol. 2010 Nov;10(11):1434-9. doi: 10.1016/j.intimp.2010.08.011. Epub 2010 Sep 9.

PMID:
20832515
23.

Effect of the inosine 5'-monophosphate dehydrogenase inhibitor BMS-566419 on rat cardiac allograft rejection.

Nakanishi T, Morokata T, Kubo K, Umeno H, Eikyu Y, Kozuki Y, Seki N.

Int Immunopharmacol. 2010 Jan;10(1):91-7. doi: 10.1016/j.intimp.2009.09.026. Epub 2009 Oct 18.

PMID:
19840872
24.

Synthesis, biological evaluation, and metabolic stability of acrylamide derivatives as novel CCR3 antagonists.

Sato I, Morihira K, Inami H, Kubota H, Morokata T, Suzuki K, Ohno K, Iura Y, Nitta A, Imaoka T, Takahashi T, Takeuchi M, Ohta M, Tsukamoto S.

Bioorg Med Chem. 2009 Aug 15;17(16):5989-6002. doi: 10.1016/j.bmc.2009.06.066. Epub 2009 Jul 3.

PMID:
19620010
25.

Design and synthesis of 6-fluoro-2-naphthyl derivatives as novel CCR3 antagonists with reduced CYP2D6 inhibition.

Sato I, Morihira K, Inami H, Kubota H, Morokata T, Suzuki K, Iura Y, Nitta A, Imaoka T, Takahashi T, Takeuchi M, Ohta M, Tsukamoto S.

Bioorg Med Chem. 2008 Sep 15;16(18):8607-18. doi: 10.1016/j.bmc.2008.08.006. Epub 2008 Aug 7.

PMID:
18752960
26.

Expression profiles of cytokines and chemokines in murine MDR1a-/- colitis.

Masunaga Y, Noto T, Suzuki K, Takahashi K, Shimizu Y, Morokata T.

Inflamm Res. 2007 Nov;56(11):439-46. doi: 10.1007/s00011-007-6078-6.

PMID:
18224285
27.

Synthesis and structure-activity relationships of N-{1-[(6-fluoro-2-naphthyl)methyl]piperidin-4-yl}benzamide derivatives as novel CCR3 antagonists.

Sato I, Morihira K, Inami H, Kubota H, Morokata T, Suzuki K, Hamada N, Iura Y, Nitta A, Imaoka T, Takahashi T, Takeuchi M, Ohta M, Tsukamoto S.

Bioorg Med Chem. 2008 Jan 1;16(1):144-56. Epub 2007 Oct 5. Erratum in: Bioorg Med Chem. 2008 Jul 15;16(14):1078.

PMID:
17951061
28.

A dual antagonist for chemokine CCR3 receptor and histamine H1 receptor.

Suzuki K, Morokata T, Morihira K, Sato I, Takizawa S, Kaneko M, Takahashi K, Shimizu Y.

Eur J Pharmacol. 2007 Jun 1;563(1-3):224-32. Epub 2007 Feb 8.

PMID:
17336292
29.

YM-58483, a selective CRAC channel inhibitor, prevents antigen-induced airway eosinophilia and late phase asthmatic responses via Th2 cytokine inhibition in animal models.

Yoshino T, Ishikawa J, Ohga K, Morokata T, Takezawa R, Morio H, Okada Y, Honda K, Yamada T.

Eur J Pharmacol. 2007 Apr 10;560(2-3):225-33. Epub 2007 Jan 19.

PMID:
17307161
30.

In vitro and in vivo characterization of a novel CCR3 antagonist, YM-344031.

Suzuki K, Morokata T, Morihira K, Sato I, Takizawa S, Kaneko M, Takahashi K, Shimizu Y.

Biochem Biophys Res Commun. 2006 Jan 27;339(4):1217-23. Epub 2005 Dec 5.

PMID:
16343433
31.

A novel, selective, and orally available antagonist for CC chemokine receptor 3.

Morokata T, Suzuki K, Masunaga Y, Taguchi K, Morihira K, Sato I, Fujii M, Takizawa S, Torii Y, Yamamoto N, Kaneko M, Yamada T, Takahashi K, Shimizu Y.

J Pharmacol Exp Ther. 2006 Apr;317(1):244-50. Epub 2005 Dec 9.

PMID:
16339911
32.

Effect of a novel interleukin-5 receptor antagonist, YM-90709, on antigen-induced eosinophil infiltration into the airway of BDF1 mice.

Morokata T, Suzuki K, Ida K, Yamada T.

Immunol Lett. 2005 Apr 15;98(1):161-5. Epub 2004 Nov 28.

PMID:
15790522
33.
34.
35.

Effect of a novel anti-inflammatory compound, YM976, on antigen-induced eosinophil infiltration into the lungs in rats, mice, and ferrets.

Aoki M, Fukunaga M, Kitagawa M, Hayashi K, Morokata T, Ishikawa G, Kubo S, Yamada T.

J Pharmacol Exp Ther. 2000 Dec;295(3):1149-55.

PMID:
11082452
36.
38.
39.

Costimulatory effect of IL-12 on the activation of naive, memory CD4+ T cells, and Th1 clone.

Kato T, Morokata T, Igarashi O, Yee ST, Inobe M, Uede T, Azuma M, Okumura K, Nariuchi H.

Cell Immunol. 1997 Feb 25;176(1):50-8.

PMID:
9070317
40.

Early activation signal transduction pathways of Th1 and Th2 cell clones stimulated with anti-CD3. Roles of protein tyrosine kinases in the signal for IL-2 and IL-4 production.

Tamura T, Nakano H, Nagase H, Morokata T, Igarashi O, Oshimi Y, Miyazaki S, Nariuchi H.

J Immunol. 1995 Nov 15;155(10):4692-701.

PMID:
7594469

Supplemental Content

Loading ...
Support Center